ASCO Draft Recommendations For Cancer Trial Endpoints
This article was originally published in The Pink Sheet Daily
The American Society of Clinical Oncology’s Cancer Research Committee has published recommendations for endpoints in Phase III trials for four different kinds of cancer and is accepting comment from stakeholders until May 1.
You may also be interested in...
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.